MSB11022

· Fresenius Kabi SwissBioSim GmbH

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MSB11022, covering 2019-02-19 to 2019-04-23. Get the full timeline:

Most recent: Clinical Trial Update: MSB11022 in Moderate to Severe Rheumatoid Arthritis [Phase 3]